Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, The company advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
Company profile
Ticker
BSX, BSX+A
Exchange
Website
CEO
Michael Mahoney
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Baxter International • Stryker • Becton, Dickinson And • 3M • Teleflex • Resmed • West Pharmaceutical Services • Haemonetics • Hill-Rom • Nuvasive ...
SEC CIK
Corporate docs
Subsidiaries
Acurate Industria e Comercio Ltda. • American Medical Systems Europe B.V. • Baylis Medical UK Limited • BAYLIS Medical (Deutschland) GmbH • Baylis Medical Company Inc. • Baylis Medical France S.A.R.L. • Baylis Medical USA Inc. • Biocompatibles UK Limited • Biocompatibles, Inc. • Boston Scientific (Malaysia) Sdn. Bhd. ...
IRS number
42695240
BSX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
DEFR14A
Revised proxy
22 Mar 23
DEFA14A
Additional proxy soliciting materials
22 Mar 23
DEF 14A
Definitive proxy
22 Mar 23
ARS
2022 FY
Annual report to shareholders
22 Mar 23
8-K
Other Events
1 Mar 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Boston Scientific Announces Results for Fourth Quarter and Full Year 2022
1 Feb 23
8-K
Departure of Directors or Certain Officers
31 Jan 23
8-K
Departure of Directors or Certain Officers
21 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
Transcripts
BSX
Earnings call transcript
2022 Q4
1 Feb 23
BSX
Earnings call transcript
2022 Q3
26 Oct 22
BSX
Earnings call transcript
2022 Q2
27 Jul 22
BSX
Earnings call transcript
2022 Q1
27 Apr 22
BSX
Earnings call transcript
2021 Q4
2 Feb 22
BSX
Earnings call transcript
2021 Q3
27 Oct 21
BSX
Earnings call transcript
2021 Q2
27 Jul 21
BSX
Earnings call transcript
2021 Q1
28 Apr 21
BSX
Earnings call transcript
2020 Q4
3 Feb 21
BSX
Earnings call transcript
2020 Q3
28 Oct 20
Latest ownership filings
4
Arthur C Butcher
24 Mar 23
4
Wendy Carruthers
16 Mar 23
4
Daniel J. Brennan
2 Mar 23
4
Jonathan Monson
2 Mar 23
4
Eric Francis Yves Thepaut
22 Feb 23
4
John Bradley Sorenson
22 Feb 23
4
Jonathan Monson
22 Feb 23
4
Joseph Michael Fitzgerald
22 Feb 23
4
Vance R Brown
22 Feb 23
4
Wendy Carruthers
22 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.13 bn | 1.13 bn | 1.13 bn | 1.13 bn | 1.13 bn | 1.13 bn |
| Cash burn (monthly) | (no burn) | 86.83 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 258.29 mm | n/a | n/a | n/a | n/a |
| Cash remaining | n/a | 867.71 mm | n/a | n/a | n/a | n/a |
| Runway (months of cash) | n/a | 10.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2022
90.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 892 |
| Opened positions | 141 |
| Closed positions | 78 |
| Increased positions | 318 |
| Reduced positions | 298 |
| 13F shares | Current |
|---|---|
| Total value | 59.68 tn |
| Total shares | 1.30 bn |
| Total puts | 5.14 mm |
| Total calls | 3.35 mm |
| Total put/call ratio | 1.5 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 135.46 mm | $6.27 tn |
| Vanguard | 118.77 mm | $5.50 tn |
| FMR | 101.18 mm | $4.68 tn |
| Massachusetts Financial Services | 81.98 mm | $3.79 tn |
| STT State Street | 63.56 mm | $2.94 tn |
| Wellington Management | 57.74 mm | $2.67 tn |
| JPM JPMorgan Chase & Co. | 47.43 mm | $2.19 tn |
| Primecap Management | 37.65 mm | $1.74 tn |
| Geode Capital Management | 24.86 mm | $1.15 tn |
| Bollard | 24.46 mm | $1.13 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Mar 23 | Arthur C Butcher | Common Stock | Sell | Dispose S | No | Yes | 47.97 | 6,703 | 321.54 k | 22,981 |
| 15 Mar 23 | Wendy Carruthers | Common Stock | Sell | Dispose S | No | Yes | 47.603 | 11,671 | 555.57 k | 88,636 |
| 15 Mar 23 | Wendy Carruthers | Common Stock | Option exercise | Acquire M | No | Yes | 13.08 | 2,960 | 38.72 k | 100,307 |
| 15 Mar 23 | Wendy Carruthers | Common Stock | Option exercise | Acquire M | No | Yes | 16.31 | 3,448 | 56.24 k | 97,347 |
| 15 Mar 23 | Wendy Carruthers | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 13.08 | 2,960 | 38.72 k | 26,639 |
| 15 Mar 23 | Wendy Carruthers | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 16.31 | 3,448 | 56.24 k | 31,034 |
| 2 Mar 23 | Daniel J. Brennan | Common Stock | Sell | Dispose S | No | Yes | 46.6638 | 30,000 | 1.40 mm | 225,958 |
| 1 Mar 23 | Jonathan Monson | Common Stock | Sell | Dispose S | No | Yes | 46.663 | 5,000 | 233.31 k | 34,868 |
| 1 Mar 23 | Jonathan Monson | Common Stock | Option exercise | Acquire M | No | Yes | 12.89 | 5,000 | 64.45 k | 39,868 |
| 1 Mar 23 | Jonathan Monson | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 12.89 | 5,000 | 64.45 k | 5,000 |
News
Analyst Expectations for Boston Scientific's Future
29 Mar 23
UBS Initiates Coverage On Boston Scientific with Buy Rating, Announces Price Target of $57
29 Mar 23
Looking Into Boston Scientific's Recent Short Interest
10 Mar 23
8 Analysts Have This to Say About Boston Scientific
2 Feb 23
JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $55
2 Feb 23
Press releases
BOSTON SCIENTIFIC INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Boston Scientific Corporation - BSX
17 Feb 23
Boston Scientific to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference
13 Feb 23
BOSTON SCIENTIFIC INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Boston Scientific Corporation - BSX
3 Feb 23
Boston Scientific Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System
3 Feb 23
Global Remote Patient Monitoring (RPM) Market Report 2023-2028
1 Feb 23